NASDAQ:NXTCNextCure Stock Price, Forecast & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NXTC shares have decreased by 53.2% and is now trading at $17.88. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) announced its quarterly earnings data on Thursday, May, 7th. The company reported $0.33 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.44) by $0.77. The business earned $22.38 million during the quarter, compared to analysts' expectations of $1.30 million. NextCure had a negative return on equity of 7.12% and a negative net margin of 65.22%. View NextCure's earnings history.

9 equities research analysts have issued 12-month price objectives for NextCure's stock. Their forecasts range from $40.00 to $87.00. On average, they expect NextCure's share price to reach $64.67 in the next twelve months. This suggests a possible upside of 261.7% from the stock's current price. View analysts' price targets for NextCure.

Press coverage about NXTC stock has trended neutral recently, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. NextCure earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about NextCure.

NextCure saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,740,000 shares, an increase of 41.5% from the June 15th total of 1,230,000 shares. Based on an average daily trading volume, of 301,900 shares, the short-interest ratio is presently 5.8 days. Currently, 10.7% of the shares of the company are sold short. View NextCure's Current Options Chain.

Some companies that are related to NextCure include Principia Biopharma (PRNB), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Ligand Pharmaceuticals (LGND), Dicerna Pharmaceuticals (DRNA), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Myovant Sciences (MYOV), Aurinia Pharmaceuticals (AUPH), Madrigal Pharmaceuticals (MDGL), I-Mab (IMAB), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME) and Ironwood Pharmaceuticals (IRWD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Amgen (AMGN), Alibaba Group (BABA), CVS Health (CVS), Dicerna Pharmaceuticals (DRNA), UnitedHealth Group (UNH), Honeywell International (HON), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T) and Arena Pharmaceuticals (ARNA).

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $17.88.

NextCure has a market capitalization of $492.06 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]